Skip to main content


Correction to: Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy

Article metrics

  • 85 Accesses

The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:63

Correction to: J Exp Clin Cancer Res

In the original publication of this article [1], there is an error in Fig. 4A.

The corrected Fig. 4A should be:

Fig. 4

Bazedoxifene inhibits induction of STAT3 phosphorylation and cell proliferation by IL-11. a: DLD-1, HCT-116, and HCT-15 cells were starved in serum-free medium for 24 h and pre-treated with bazedoxifene (5~20 μM) for 2 h. Then, 50 ng/ml (DLD-1 cells) or 25 ng/ml IL-11 (HCT-116 and HCT-15 cells), 50 ng/ml OSM (DLD-1 cells) and 50 ng/ml IFN-γ (DLD-1 cells) were added for stimulation. The p-STAT3Y705, p-STAT1Y701, STAT3, STAT1 and GAPDH were assessed by western blot analysis.


  1. 1.

    Wei, et al. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy. J Exp Clin Cancer Res. 2019;38:63.

Download references

Author information

Correspondence to Jiayuh Lin.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article